Molecular Mechanisms of Treatment Resistance in Prostate Cancer
A Special Issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 15 September 2026 | Viewed by 2765
Editor
Interests: androgen receptor; prostate cancer; treatment resistance; cell signaling pathways; SEMA3C
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Metastatic castration-resistant prostate cancer (mCRPC) remains a difficult clinical challenge, driven by tumor heterogeneity, diverse progression pathways and complex resistance mechanisms. This Special Issue, “Molecular Mechanisms of Treatment Resistance in Prostate Cancer”, seeks original research and comprehensive reviews on the following topics:
- Precision systemic therapies, including approaches against traditionally “undruggable” targets.
- Genetic and epigenetic alterations driving disease progression.
- The role of cellular plasticity and lineage reprogramming.
- Tumor microenvironment signaling and therapeutic modulation.
- Mechanisms of resistance to current androgen‐targeted and cytotoxic treatments.
- Immunotherapeutic strategies and combination therapies.
- Targeted radiotherapy, including radioligand approaches.
- Novel biomarkers for patient stratification and treatment response monitoring.
The aim of this Special Issue is to deepen our understanding of the complex mechanisms driving mCRPC and to showcase innovative therapeutic avenues that can improve patient survival and quality of life.
Dr. Christopher J. Ong
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metastatic castration-resistant prostate cancer (mCRPC)
- molecular mechanisms
- novel treatment strategies
- systemic precision treatments
- epigenetics
- cellular plasticity
- tumor microenvironment signaling
- therapeutic resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
